首页> 外文会议>Annual International Conference of the IEEE Engineering in Medicine and Biology Society >Predictive models for diffuse low-grade glioma patients under chemotherapy
【24h】

Predictive models for diffuse low-grade glioma patients under chemotherapy

机译:化疗下弥漫性低级胶质瘤患者的预测模型

获取原文

摘要

Diffuse low-grade gliomas are rare primitive cerebral tumours of adults. These tumors progress continuously over time and then turn to a higher grade of malignancy associated with neurological disability, leading ultimately to death. Tumour size is one of the most important prognostic factors. Thus, it is of great importance to be able to assess the volume of the tumor during the patients' monitoring. MRI is nowadays the recommended modality to achieve this. Furthermore, if surgery remains the first option for diffuse low-grade gliomas, chemotherapy is increasingly used (before or after a possible surgery). However, crucial and difficult questions remain to be answered: identifying subgroups of patients who could benefit from chemotherapy, determining the best time to initiate chemotherapy, defining the duration of chemotherapy and evaluating the optimal time to perform surgery, or otherwise radiotherapy. In this study, we propose to help clinicians in decision-making, by designing new predictive models dedicated to the evolution of the diameter of the tumor. Two proposed statistical models (linear and exponential) have been validated on a database of 16 patients whose temozolomide-based chemotherapy lasted between 14 and 32 months, with an average duration of 22.8 months. The selection of the most appropriate model has been achieved with the corrected Akaike's Information Criterion. The results are very promising, with coefficients of determination varying from 0.79 to 0.97 with an average value of 0.90 for the linear model. This shows it is possible to alert the clinician to a change in the tumor diameter's dynamics.
机译:弥漫性低级胶质瘤是成人的罕见原始脑肿瘤。这些肿瘤随着时间的推移不断进行,然后转向与神经病学残疾相关的更高等级,最终导致死亡。肿瘤大小是最重要的预后因素之一。因此,能够在患者监测期间评估肿瘤的体积非常重要。现在MRI是建议实现这一目标的推荐方式。此外,如果手术仍然是弥漫性低级胶质瘤的第一种选择,则越来越多地使用化疗(在可能的手术之前或之后)。然而,关键和难题仍有待解答:鉴定可以从化疗中受益的患者的亚组,确定发起化疗的最佳时间,定义化疗持续时间并评估进行手术的最佳时间,或其他放射治疗。在这项研究中,我们建议通过设计致力于肿瘤直径的演变的新预测模型来帮助临床医生。两种提出的统计模型(线性和指数)已验证到16名患者的替替替莫族化疗持续14至32个月的患者的数据库上,平均持续时间为22.8个月。通过纠正的Akaike的信息标准,已经实现了最合适的模型的选择。结果非常有前途,测定系数从0.79到0.97变化,线性模型的平均值为0.90。这表明可以提醒临床医生对肿瘤直径的动态的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号